#ccRCC
Uncovering #TumorMicroenvironment determinants of TKI response in metastatic #ccRCC.
#SpatialTranscriptomics reveals distinct immune and angiogenic profiles in responders and non-responders, identifying mechanisms of drug resistance. @mdanderson.bsky.social
#OpenAccess: doi.org/10.1038/s413...
November 13, 2026 at 9:30 AM
MERCK RECEIVES POSITIVE EU CHMP OPINION FOR WELIREG® (BELZUTIFAN) IN COMBINATION WITH LENVATINIB FOR ADULTS WITH ADVANCED RENAL CELL CARCINOMA WITH A CLEAR CELL COMPONENT (CCRCC) FOLLOWING TREATMENT WITH AN ANTI :PD
November 13, 2026 at 11:39 AM
Trial NCT02855203: SABR + pembrolizumab in 30 oligometastatic ccRCC patients showed promising safety. Key outcomes: overall survival, local progression, and control rates. PMID:42420295, Nat Commun 2026, @NatureComms https://doi.org/10.1038/s41467-026-74255-x #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma | Nature Communications
Biomarkers that predict response to combined radiation and anti-PD-1 therapy in clear cell renal cell carcinoma (ccRCC) are poorly defined. RAPPORT trial (NCT02855203) is a prospective phase I/II study of stereotactic ablative body radiotherapy (SABR) and pembrolizumab in 30 patients with oligometastatic ccRCC. The primary endpoint was safety; secondary endpoints included overall survival, time to local progression, distant progression-free survival, objective and disease control rates, duration of response and patient-reported pain. Here, we report the pre-specified exploratory translational analyses. In pre-treatment tumours, responders had greater intra-tumoural cytotoxic T cell infiltration in close proximity to tumour cells, whereas non-responders showed enrichment of immunosuppressive, TGF-β and angiogenic signatures. In peripheral blood post-treatment, responders developed a proliferative burst of activated CD8+ T cells and sustained sharing of pre-existing tumour-enriched TCR c
doi.org
November 5, 2026 at 9:00 PM
How does adipose tissue-derived LPE18:1 fuel #ccRCC?

By stabilizing #SIRT6 through the CAPZA1/USP48 axis, it reprograms lipid metabolism toward free cholesterol accumulation and promotes tumor progression.

#STTT #OpenAccess: doi.org/10.1038/s413...
November 8, 2026 at 3:01 AM
Despite a lack of responses in the phase 2 LASER trial, Praful Ravi, MB, BChir, MRCP, of @danafarber.bsky.social explains how the outcome could help inform future research with radioligand therapy in advanced RCC #kcsm #oncology www.onclive.com/view/lutetiu...
Lutetium Lu 177 Vipivotide Tetraxetan Yields No Responses in PSMA+ ccRCC | OncLive
Praful Ravi, MB, BChir, MRCP, discusses the LASER futility readout, PSMA heterogeneity in clear cell RCC, and next steps for radiopharmaceuticals.
www.onclive.com
November 3, 2026 at 3:59 PM
RRIDs were included in this in Nature Communications paper. RRIDs improve reproducibility in scientific research. #ReproducibleResearch #methodsmatter #RRID
SWI/SNF ATPase silenced HLF potentiates lung metastasis in solid cancers - Nature Communications
Clear cell renal cell carcinoma (ccRCC) usually metastasizes to the lungs. Here, the authors discover that SWI/SNF ATPase subunit SMARCA4 silencing of HLF regulates ccRCC lung metastasis by modulating the integration of collagen's mechanical cues with the actin cytoskeleton through leupaxin.
doi.org
October 30, 2026 at 7:03 AM
Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti–PD-(L)1 therapy www.annalsofoncology.org/article/S092...
Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti–PD-(L)1 therapy
The phase 3, randomized, open-label LITESPARK-011 trial (NCT04586231) investigated belzutifan plus lenvatinib versus cabozantinib in participants with advanced clear-cell renal-cell carcinoma (ccRCC) ...
www.annalsofoncology.org
October 30, 2026 at 11:49 AM
Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study www.annalsofoncology.org/article/S092...
Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study
Pembrolizumab plus lenvatinib is a first-line standard of care for advanced clear-cell renal-cell carcinoma (ccRCC). The phase 3 LITESPARK-012 study (NCT04736706) evaluated efficacy and safety of addi...
www.annalsofoncology.org
October 30, 2026 at 11:47 AM
A new #PETimaging approach detected 97.9% of lesions in clear cell renal cell carcinoma, potentially giving clinicians a more complete picture of the location and extent of a patient’s disease. The research was presented at @eanm.org's #EANM26 congress in 🇦🇹 Vienna. #ccRCC #kidneycancer
ccRCC kidney cancer: PET/CT imaging approach improves lesion detection
Research was presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM’26)
healthcare-in-europe.com
October 26, 2026 at 11:41 AM
(JPR) Hypoxia Signatures
in Renal Cell Carcinoma: From HIF-Mediated
Omics Remodeling to Precision Diagnostics: AbstractRenal cell carcinoma (RCC), particularly clear cell RCC
(ccRCC),
exhibits extensive metabolic, signaling, and microenvironmental remodeling
associated with… #MassSpecRSS
Hypoxia Signatures in Renal Cell Carcinoma: From HIF-Mediated Omics Remodeling to Precision Diagnostics
AbstractRenal cell carcinoma (RCC), particularly clear cell RCC (ccRCC), exhibits extensive metabolic, signaling, and microenvironmental remodeling associated with dysregulated VHL-HIF signaling. HIF activation in RCC may arise from VHL loss under normoxic conditions and from genuine tumor hypoxia due to inadequate oxygen availability; these states can converge on overlapping downstream programs but are biologically distinct. This review examines proteomic, phosphoproteomic, metabolomic, and emerging spatial and single-cell studies that characterize hypoxia- and VHL-HIF-associated molecular alterations in RCC. Particular emphasis is placed on protein-level changes in metabolism, angiogenesis, extracellular matrix remodeling, signaling, and immune regulation, as well as on how these measurements complement transcriptomic data. The review further distinguishes mechanistic molecular signatures from candidate diagnostic, prognostic, predictive, pharmacodynamic, and treatment-selection biomarkers. Evidence for circulating proteins and metabolites is discussed together with available measures of diagnostic performance, analytical validation, and clinical validation. Finally, the potential of integrated discovery and targeted mass-spectrometry approaches to support clinically useful multianalyte biomarker panel development is considered, while highlighting the challenges of tumor heterogeneity, assay reproducibility, cohort validation, and clinical utility.
dlvr.it
October 27, 2026 at 8:01 AM
@drchoueiri.bsky.social presents the final protocol-prespecified analysis of the phase 3 KEYNOTE-564 trial, evaluating adjuvant pembrolizumab versus placebo in patients with clear cell renal cell carcinoma (ccRCC). #ESMO26
October 25, 2026 at 1:54 PM
🆕 The final prespecified analysis of the KEYNOTE-564 trial demonstrated continued efficacy benefits with adjuvant pembrolizumab therapy for patients with ccRCC

Presented by @drchoueiri.bsky.social (@danafarber.bsky.social) at #ESMO26 @myesmo.bsky.social

More data: https://bit.ly/4e1QYhU
October 26, 2026 at 5:16 PM

OncoAlert🚨 #ESMO26 #Podium2Screen Series: XmAb819 in #RCC

Our @OncoAlert founding faculty @montypal presents a first-in-class ENPP3 x CD3 bispecific in heavily pretreated ccRCC:

➡️ ORR 27%, DCR 68%
➡️ Activity after prior HIF-2α inhibitor (ORR 26%)
➡️ 15/16 responders still on treatment
October 25, 2026 at 9:41 AM
OncoAlert founding faculty Dr. Toni Choueiri 🇺🇸 of Dana Farber walks us through adjuvant pembrolizumab vs placebo in high-risk ccRCC:

📊 DFS HR 0.68 | 7-yr DFS 57.2% vs 44.6%
📊 OS HR 0.70 | 7-yr OS 82.3% vs 76.6%
✅ No new safety signals
Durable benefit. Standard of care confirmed.
October 25, 2026 at 2:12 PM
The Harpswell Fire & Rescue Planning Committee is uncovering significant discrepancies in ambulance dispatch data that could reshape their response strategy.

Read the full story

#HarpswellCumberlandCounty #ME #CitizenPortal #HarpswellFireRescue #PublicSafety #HealthcareAccess
Harpswell committee reviews MC1/MC2 dispatching and fly‑car obligations
Committee members and a visiting director reviewed annual dispatch counts for MC1 and MC2, discussed CAD/CCRCC auto‑assignment behavior, and debated whether renegotiating the fly‑car contract is necessary to avoid routine transport obligations.
citizenportal.ai
October 24, 2026 at 7:40 PM
(BioRxiv All) Expanding the HIF-2α proteomic interactome with TurboID proximity labeling.: The transcription factor HIF2 is a central regulator of cellular adaptation to hypoxia, orchestrating gene expression programs that control angiogenesis, erythropoiesis, and metabolic… #BioRxiv #MassSpecRSS
Expanding the HIF-2α proteomic interactome with TurboID proximity labeling.
The transcription factor HIF2 is a central regulator of cellular adaptation to hypoxia, orchestrating gene expression programs that control angiogenesis, erythropoiesis, and metabolic reprogramming, and is famously overexpressed in cancers such as clear cell Renal Cell Carcinoma (ccRCC). While the gene targets of HIF2 have been extensively characterized, the composition and dynamics of its protein interaction network remain less well defined. In this study, we sought to systematically characterize proteins associated with HIF2 using two distinct proteomic approaches, enabling the identification of both stable binding partners and transient or indirect interactors. We integrated affinity purification mass spectrometry with proximity labeling strategies, thus expanding the existing interactome of HIF2 to include uniquely identified proteins and complexes such as members of the nuclear pore complex. Across both immunoprecipitation mass spectrometry (IP MS) and TurboID MS, we identified 888 and 1,048 proteins, respectively. We applied stringent filtering criteria to refine both datatsets, yielding a dataset of 329 HIF2 interacting proteins, approximately 75% of which have yet to be documented as HIF2 interactors. We queried this set across publicly available cancer genomics and proteomics datasets and detected expression of our interactors in breast cancer and ccRCC tumor proteomes. These findings led us to identify GRHL2 and KIF4A as proteomic interactors that contribute to poor patient survival in breast cancer. Taken together, we herein provide a comprehensive resource of HIF2 interacting proteins which provide insights into the mechanisms by which HIF2 drives disease progression.
dlvr.it
October 24, 2026 at 1:02 AM
OncoAlert 4Sight Abstracts to be Presented at #ESMO26
Final Protocol-Prespecified Analysis of the Phase 3 KEYNOTE-564 Trial of Adjuvant Pembrolizumab Versus Placebo in Clear Cell Renal Cell Carcinoma (ccRCC)
October 22, 2026 at 3:01 PM
Targeted PET/CT detected 97.9% of clear cell kidney cancer lesions versus 47.1% with FDG PET/CT. The findings still need validation in larger patient populations.
New PET imaging approach detects almost all lesions in common form of kidney cancer
A new PET imaging approach detected 97.9% of lesions in clear cell renal cell carcinoma (ccRCC), potentially giving clinicians a more complete picture of the location and extent of a patient's disease, according to research presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM'26).
medicalxpress.com
October 20, 2026 at 7:50 AM
Transcriptomic analysis of clear cell renal cell carcinoma (ccRCC) reveals dysregulated sulfatase, nucleotide sugar, glycosyltransferase and glycosaminoglycan pathways.

tinyurl.com/msdsttrb

#glycotime
October 12, 2026 at 7:30 AM
💊FDA Approvals | Notable Recent Oncology Drugs
🔹#Atezolizumab + chemo— Stage III dMMR colon cancer
🔹#Tucatinib combo— HER2+ breast cancer
🔹#Pirtobrutinib— BTK inhibitor for CLL/SLL
🔹#Belzutifan + #Lenvatinib— advanced ccRCC

🔎Discover bioactive molecules for your research: https://ow.ly/2s0R50ZWcts
October 9, 2026 at 11:00 AM
Casdatifan, a potent HIF-2α inhibitor, shows durable antitumor activity in refractory metastatic ccRCC per ARC-20 study (NCT05536141). Manageable safety. PMID:42386974, Nature 2026, @Nature https://doi.org/10.1038/s41586-026-10718-x #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer | Nature
Clear cell renal cell carcinoma (ccRCC) is largely driven by the transcription factor hypoxia-inducible factor 2α (HIF-2α)1. Here we show that monotherapy with casdatifan—an orally bioavailable, potent and selective HIF-2α inhibitor2—produces meaningful, durable antitumour activity with manageable safety in individuals with refractory metastatic ccRCC. Dose-expansion data from the ARC-20 study ( NCT05536141 ) are presented, including for the 100 mg once daily (QD) cohort (n = 32) and the total cohort (n = 127). Treatment discontinuation from casdatifan-related adverse events was infrequent (3%), and class-effect toxicities included anaemia and hypoxia. The confirmed objective response rates (ORRs) were 35% (95% confidence intervals (CI) = 19–55%; 100 mg QD) and 31% (95% CI = 23–40%; total); median progression-free survival (PFS) was not estimable (95% CI = 5.7–not estimable; 100 mg QD) and 12.2 months (9.4–20.6; total). Greater maximal reductions in serum
doi.org
October 8, 2026 at 11:00 PM